Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB
Clinical trial NCT06205589 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06205589
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-01
- Primary completion
- 2028-10-31
- Enrollment
- 1500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.